Parkinson’s disease is a progressive neurodegenerative disorder marked by motor symptoms such as tremor, slowness of movement, rigidity and balance problems, along with non motor symptoms including sleep disturbances, mood changes and cognitive decline. It is primarily linked to the gradual loss of dopamine producing neurons in a brain region called the substantia nigra, and to abnormal aggregates of the protein alpha synuclein that form Lewy bodies.

Research points to a complex interplay between genetic and environmental factors. Certain gene variants, including mutations in SNCA, LRRK2 and GBA, increase risk, while exposure to pesticides, solvents and air pollution has been associated with higher incidence. Conversely, regular physical activity, caffeine and smoking show epidemiological associations with reduced risk, although smoking is obviously harmful overall.

Current treatments mainly address symptoms rather than stopping the disease. Standard therapies increase or mimic dopamine, such as levodopa and dopamine agonists, while deep brain stimulation uses implanted electrodes to modulate abnormal brain activity. These approaches can greatly improve quality of life but tend to lose effectiveness or cause complications over time.

Active research is exploring disease modifying strategies. These include immunotherapies that target alpha synuclein, drugs that enhance cellular waste disposal systems, and approaches aimed at protecting or restoring dopamine neurons through neurotrophic factors or cell replacement. Scientists are also examining the role of the gut microbiome, chronic inflammation and mitochondrial dysfunction in disease onset and progression.

Improved biomarkers using imaging, fluid tests and digital monitoring aim to detect Parkinson’s earlier and track it more precisely, enabling better clinical trials and more personalized treatment strategies in the future.